Form 4: Seres Therapeutics Executive Acquires Stock Options
Statement of Changes in Beneficial Ownership
Thomas DesRosier, EVP and Chief Legal Officer of Seres Therapeutics, acquired 7,500 stock options on July 8, 2026.
Summary
- Thomas DesRosier, the Executive Vice President and Chief Legal Officer of Seres Therapeutics, Inc., was granted 7,500 stock options on July 8, 2026.
- These options have an exercise price of $9.13 and are set to expire on March 3, 2036.
- The options vest over time, with 25% becoming available on March 2, 2027, and the remaining shares vesting in 12 equal quarterly installments thereafter.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard executive stock option grant without providing new financial information or strategic updates.
Positives
- Grant of stock options to a key executive, indicating potential alignment of executive interests with shareholder value.
- The options provide a long-term incentive with an expiration date in 2036.
Risks
- The value of the stock options is contingent on the future performance of Seres Therapeutics' stock price.
- Vesting schedules mean the executive cannot immediately benefit from the full grant.
Future Outlook
The filing does not contain forward-looking statements or guidance regarding the company's financial performance. It solely reports a transaction related to executive compensation.
Industry Context
StockSavvy.ai notes that the granting of stock options to executives is a common practice in the biotechnology and pharmaceutical sectors, used to attract, retain, and incentivize key personnel by aligning their financial interests with the long-term success of the company.
Stakeholder Impact
- Shareholders: The grant of options to executives is a standard compensation practice. The ultimate impact on shareholders will depend on the company's future stock performance and the executive's ability to exercise these options profitably.
Key Dates
| Date | Description |
|---|---|
| 07/08/2026 | Earliest transaction date and date of stock option grant. |
| 03/02/2027 | First vesting date for 25% of the stock options. |
| 03/03/2036 | Expiration date of the stock options. |
Keywords
Seres Therapeutics, MCRB, Form 4, Stock Options, Executive Compensation, Insider Trading, Beneficial Ownership, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.